ACALABRUTINIB

Search structure
Trade Names:
Synonyms:
Status: Approved (2017)
Entry Type: Small molecule
Molecule Category: UNKNOWN
UNII: I42748ELQW

Structure
InChI Key WDENQIQQYWYTPO-IBGZPJMESA-N
Smile CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12
InChI
InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C26H23N7O2
Molecular Weight 465.52
AlogP 3.31
Hydrogen Bond Acceptor 7.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 4.0
Polar Surface Area 118.51
Molecular species NEUTRAL
Aromatic Rings 4.0
Heavy Atoms 35.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Tyrosine-protein kinase BTK inhibitor FDA
Primary Target
Bruton tyrosine kinase
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Adhesion
- 1210 - - -
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase Alk family
- - - - 2
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase EGFR family
- 1000 140 -
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase JakA family
- - - -
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase JakB family
- - - -
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase Src family
- - - - 16
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase Tec family
- 3-747 14 - 100
Membrane receptor
- 1210 - - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Lymphoma, Mantle-Cell 4 D020522 ClinicalTrials
Severe Acute Respiratory Syndrome 3 D045169 ClinicalTrials
Lymphoma, Large B-Cell, Diffuse 3 D016403 ClinicalTrials
Carcinoma, Squamous Cell 2 D002294 ClinicalTrials
Pancreatic Neoplasms 2 D010190 ClinicalTrials
Carcinoma, Non-Small-Cell Lung 2 D002289 ClinicalTrials
Lymphoma, Non-Hodgkin 2 D008228 ClinicalTrials
Waldenstrom Macroglobulinemia 2 D008258 ClinicalTrials
Ovarian Neoplasms 2 D010051 ClinicalTrials
Graft vs Host Disease 2 D006086 ClinicalTrials
Lymphoma, Follicular 2 D008224 ClinicalTrials
Lymphoma, Follicular 2 D008224 ClinicalTrials
Lymphoma 2 D008223 ClinicalTrials
Arthritis, Rheumatoid 2 D001172 ClinicalTrials
Hematologic Neoplasms 2 D019337 ClinicalTrials
Leukemia 1 D007938 ClinicalTrials
Glioblastoma 1 D005909 ClinicalTrials
Multiple Myeloma 1 D009101 ClinicalTrials
Leukemia, Prolymphocytic 1 D015463 ClinicalTrials
Neoplasms 1 D009369 ClinicalTrials
Communicable Diseases 1 D003141 ClinicalTrials

Related Entries

Scaffolds

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Infections and infestations
16.04
Gastrointestinal disorders
11.37
Respiratory, thoracic and mediastinal disorders
11.21
General disorders and administration site conditions
8.62
Cardiac disorders
8.13
Nervous system disorders
7.15
Vascular disorders
6.27
Blood and lymphatic system disorders
4.38
Skin and subcutaneous tissue disorders
4.08
Injury, poisoning and procedural complications
3.43
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
3.23
Immune system disorders
3.07
Metabolism and nutrition disorders
3.04
Musculoskeletal and connective tissue disorders
2.58
Renal and urinary disorders
2.29

Cross References

Resources Reference
CAS NUMBER 1420477-60-6
ChEBI 167707
ChEMBL CHEMBL3707348
DrugBank DB11703
DrugCentral 5260
FDA SRS I42748ELQW
Guide to Pharmacology 8912
PubChem 71226662
SureChEMBL SCHEMBL14637368
ZINC ZINC000208774715
CONTENTS